BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Making NanoMedicine Personal:  Translating Genome-Wide Information
  & Point of Care Diagnostics into the Clinic  - Professor Matt Trau\, The 
 University of Queensland Centre for Personalised NanoMedicine
DTSTART:20160617T083000Z
DTEND:20160617T093000Z
UID:TALK66171@talks.cam.ac.uk
CONTACT:Catherine Atkins
DESCRIPTION:Modern medicine is currently transitioning to a new paradigm o
 f precision and personalized care\, where patients will be comprehensively
  screened and monitored for the detailed molecular abnormalities that char
 acterise their specific disease.  In the past decade\, nanotechnology has 
 provided new tools (e.g.\, next-generation sequencing) with unprecedented 
 power to comprehensively interrogate genetic\, transcriptomic and epigenet
 ic information.  The Centre for Personalised Nanomedicine at UQ is focused
  on translating these new technologies into a clinical setting\, whilst si
 multaneously developing the next generation of point-of-care diagnostic te
 chnologies to further empower the personalised and precision medicine appr
 oach.  As part of a major National Collaborative grant funded by the Natio
 nal Breast Cancer Foundation (“Enabling clinical epigenetic diagnostics:
  The next generation of personalized breast cancer care”\, CG-12-07)\, o
 ur consortium recently published hundreds of epigenetic regions that area 
 highly informative in cancer1-2.  These are now being validated in a real-
 time clinical setting\, where comprehensive DNA\, methyl-DNA and RNA infor
 mation is collected in tandem and analysed.  In this paper we will present
  data on the clinical translation of this approach\, highlighting some of 
 the positive impacts that such an approach can make on the “recovery tra
 jectory” of cancer patients.  Along with comprehensive DNA/RNA/methylate
 d-DNA sequencing methodologies\, several point-of-care nanotechnologies re
 cently developed by our lab will be presented3-12. These include novel tec
 hnologies for detecting circulating free DNA/RNA/methyl-DNA\, circulated t
 umour cells\, exosomes and protein biomarkers.  Several of these technolog
 ies have been developed collaboratively with US partners via a collaborati
 ve NIH grant (“Accelerated Molecular Probe Pipeline”\, U01AI082186-01)
 .     \n\nRefs:\n1) Stone\, et al.\,  Nature Communications (2015)\n2) Sti
 rzaker\, et al.\,  Nature Communications (2015)\n3) Wee\, Trau\, Nature Ch
 emistry (2014)\n4) Wang\, Wee\, Trau\, Chem Comm. (2015)\n5) Wang\, Vaidya
 nathan\, Shiddiky\; Trau\, ACS Nano (2015).\n6) Vaidyanathan\, van Leeuwen
 \, Rauf\, Shiddiky\, Trau\,  Sci Reports (2015)\n7) Grewal\, Shiddiky\, Sp
 adafora\, Cangelosi\, Trau\, J. Phys. Chem. C (2015)\n8) Wee\, Sakandar\, 
 Shiddiky\, Dobrovic\, Trau  Clinical Chem. (2015)\n9) Korbie\, Lin\, Wall\
 , Nair\, Stirzaker\, Clark\, Trau\, Clinical Epigenetics (2015)\n10) Wee\,
  Lau\, Botella\, Trau\, Chem Comm (2015)\n11) Lane\, Korbie\, Anderson\, V
 aidyanathan\, Trau\, Sci Reports (2015)\n12) Anderson\, Lane\, Korbie\, Tr
 au\, Langmuir (2015)
LOCATION:Cancer Research UK Cambridge Institute\, Lecture Theatre
END:VEVENT
END:VCALENDAR